Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Alltracel boosts Japanese firm's woundcare line:

This article was originally published in Clinica

Executive Summary

Alltracel Pharmaceuticals has entered an agreement with Japanese consumer woundcare company Nichiban to develop and market Alltracel's m.doc "stop-bleeding" technology in Japan. The initial focus is to integrate the Dublin, Ireland-based company's SEAL.ON first aid treatment range, which incorporates m.doc's fast coagulating properties, into Nichiban's portfolio of woundcare brands. The Tokyo-based firm, which holds a 23% majority share of the Japanese consumer woundcare market, says it also plans to upgrade its own line-up of existing brands by introducing m.doc technology into the products.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts